Deferred Tax Assets, Valuation Allowance of Lyra Therapeutics, Inc. from 31 Dec 2019 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Lyra Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2019 to 31 Dec 2024.
  • Lyra Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $84,810,000, a 41% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Lyra Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $84,810,000 +$24,854,000 +41% 31 Dec 2024 10-K 13 Mar 2025 2024 FY
Q4 2023 $59,956,000 +$19,444,000 +48% 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q4 2022 $40,512,000 -$14,185,000 -26% 31 Dec 2022 10-K 22 Mar 2024 2023 FY
Q4 2021 $54,697,000 +$13,246,000 +32% 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q4 2020 $41,451,000 +$6,301,000 +18% 31 Dec 2020 10-K 09 Mar 2022 2021 FY
Q4 2019 $35,150,000 31 Dec 2019 10-K 09 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.